KNAW

Research

Virgo: new intervention strategies for respiratory virus infections

Pagina-navigatie:


Update content


Title Virgo: new intervention strategies for respiratory virus infections
Period 2004 - 2008
Status Completed
Research number OND1309203

Abstract

Respiratory virus infections are among the leading causes of death in humans and animals, causing considerable suffering and economic losses worldwide. Major causes of these infections are influenza virus, respiratory syncytical virus (RSV) and also the recently discovered human metapneumovirus (hMPV), all of which have counterparts in the animal world. In the Netherlands alone, the annual costs associated with the treatment of respiratory virus infections in human exceed 300 million Euro. Influenza virus is the leading cause of these infections: Each year, 5 to 10 percent of the population suffers from influenza during the winter season. Major worldwide outbreaks of influenza are sporadic, but have caused the death of at least 50 million people in the past century. Possible future global outbreaks pose a threat not to be ignored. Intervention strategies for respiratory infections are not available at present or are only effective to a limited extent. The main objective of VIRGO is to improve the rational design of vaccination and other intervention strategies for respiratory virus infections. For the rational design and development of effective and safe preventive and therapeutic intervention strategies against microbial infections of humans and animals, understanding of the host-microbe interaction at the cellular and molecular levels is of critical importance. In the last decades knowledge about this interaction and about intervention strategies for viral infections has increased considerably but our knowledge is far from complete. By applying genomics and bioinformatics tools VIRGO is aiming at breakthroughs in the understanding of immune mediated protection as well as immune mediated pathogenesis after infection or vaccination.

Related organisations

Other involved organisations

ViroNovative BV; Intervet International BV

Related people

Contact person Dr. A.C. Andeweg

Classification

A70000 Public health and health care
D21400 Genetics
D21800 Immunology, serology
D22100 Microbiology
D23110 Infections, parasitology

Go to page top
Go back to contents
Go back to site navigation